Graham et al recently reported on the comparative effectiveness of warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) among patients with nonvalvular atrial fibrillation. This real-world study was based on Medicare claims data.1 The authors concluded that dabigatran and apixaban were associated with a more favorable benefit-harm profile than rivaroxaban in standard-dose NOAC users.
Appropriate Interpretation of the Observed NOACs Treatment Effect Size in Real-world Study
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024
About admin
Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge.
Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →